A Multicenter, Open-Label Extension Study To Evaluate The Long-Term Safety And Tolerability Of Faricimab In Patients With Diabetic Macular Edema
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 1479 participants |
| Allocation: | N/A |
| Intervention Model: | Single Group Assignment |
| Masking: | None (Open Label) |
| Masking Description: | The first 16 weeks of this study will be a masked period (to transition from the multi-arm parent studies) during which participants may receive either faricimab or sham injection. Participants and physicians will be masked only to the faricimab treatment interval. After the Week 16 treatment procedure, this study will follow an open-label design. The BCVA examiner will remain masked for the duration of this long-term extension study. |
| Primary Purpose: | Treatment |
| Official Title: | A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Patients With Diabetic Macular Edema |
| Actual Study Start Date : | August 5, 2020 |
| Estimated Primary Completion Date : | August 18, 2023 |
| Estimated Study Completion Date : | August 18, 2023 |
